Massachusetts is currently home to 3148 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
NCT04816604
Recruiting
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
NCT01790152
Recruiting
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
Gender:
ALL
Ages:
All
Trial Updated:
04/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Register for Updates
Use of Ketosis in Modulating Metabolic Pathways in Bipolar Disorder
NCT06373016
Recruiting
The goal of this clinical trial is to test how specific components of diet affect brain function and behavior for individuals with bipolar. The main question it aims to answer is how glucose and ketones each affect the brain's response to risk and reward. Participants will be asked to provide blood (to assess baseline measures of how the body uses energy), and then to receive two MRI scan sessions, on separate days. During each MRI scan session, participants will play three games, from which the... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/15/2024
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Bipolar Disorder, Bipolar Disorder Type 1
Register for Updates
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT06003153
Recruiting
The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
Register for Updates
Assessment of Left Ventricular Filling Pressure by Applying Artificial Intelligence Algorithms to Left Atrial Speckle-tracking Echocardiography
NCT05768698
Recruiting
The goal of this single-center, prospective, observational study is to validate a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization; In addition, the added value of this new automated software to detect increased LVEDP \> 15 mm Hg compared to the current ASE/EACVI algorithm for assessing diastolic dysfunction and longitudinal left atrial strain during the reservoir... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Philips Healthcare, Andover, Massachusetts
Conditions: Heart Failure, Diastolic, Echocardiography
Register for Updates
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
NCT05065554
Recruiting
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significance ( IgM MGUS) or Waldenström macroglobulinemia WM related neuropathies. The names of the study drugs involved in this study are/is: * Acalabrutinib * Rituximab or similar CD20 antibody
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
Register for Updates
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NCT04294927
Recruiting
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Gender:
FEMALE
Ages:
Between 25 years and 50 years
Trial Updated:
04/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Register for Updates
Knee Arthroplasty Activity Trial
NCT04107649
Recruiting
Total knee replacement (TKR) is a common and costly procedure widely used to relieve pain and improve function in patients with symptomatic advanced knee osteoarthritis (OA). As of 2013, the annual incidence of TKR was over 680,000 surgeries and annual costs exceeded $11 billion. Growing evidence suggests that while pain and functional status improve following TKR, physical activity (PA) typically does not surpass pre-TKR levels. Engagement in PA can meaningfully improve quality of life (QoL), p... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
04/15/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Knee Osteoarthritis, Total Knee Replacement
Register for Updates
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Recruiting
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of c... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Register for Updates
Evaluation of a Novel Class of Objective Myofascial Pain Assessments
NCT05793086
Recruiting
This is an observational study that is intended to determine the capacity of three technologies to serve as diagnostic biomarkers for myofascial pain syndrome. Investigators will seek patients with myofasical pain syndrome as well as healthy subjects for this study. Electrical impedance myography (EIM), myofiber threshold tracking (TT) excitability testing, and ultrasound with shear wave elastography (SWE) measurements will be obtained from the trapezius muscle (the muscle that extends over the... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/13/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Myofascial Pain, Trigger Point Pain, Myofascial
Register for Updates
Elranatamab in R/R Multiple Myeloma
NCT06138275
Recruiting
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Register for Updates
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
NCT06004167
Recruiting
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Register for Updates